(Date:11/5/2009)...ire-FirstCall/ -- Imagenetix, Inc. (OTC Bulletin B... President and CEO of Imagenetix, will be presenti...Conference on Thursday, December 3rd, at 10:30 AM ... LD MICRO ,, LD MICRO is a by-invitation only n... companies in the micro-cap space. Since 2002, the...
(Date:11/5/2009)...swire-FirstCall/ -- Transgenomic, Inc. (OTC Bullet...for the quarter ended September 30, 2009. The Comp...s that follow. ,, Third Quarter 2009 ,, Th... per share for the third quarter of 2009 as compar...r the third quarter of 2008. ,, Net sales were...
(Date:11/5/2009)... Wound Management Technol...ntered into a Letter of Intent to purchase all hea...ies, Inc. (OTC Bulletin Board: VHGI). The deal pro...ebt, 4,000,000 shares of WNDM and a royalty agreem...p technology being acquired from VHGI. WNDM clos...
(Date:11/5/2009)...ewswire/ -- SpineSmith Partners has signed an init...unique scaffold that mimics the structure of natur...al commercial products by SpineSmith,s Research an... GenOsteo scaffold represents a significant advanc...l environment for the delivery of adult stem cells...
Breaking Biology Technology:Imagenetix to Present at 2nd Annual LD MICRO Conference at the Luxe Sunset Bel Air 2Transgenomic, Inc. Reports Third Quarter 2009 Results 2Transgenomic, Inc. Reports Third Quarter 2009 Results 3Transgenomic, Inc. Reports Third Quarter 2009 Results 4Transgenomic, Inc. Reports Third Quarter 2009 Results 5Transgenomic, Inc. Reports Third Quarter 2009 Results 6Transgenomic, Inc. Reports Third Quarter 2009 Results 7OTCBB-WNDM Announces LOI to Acquire VHGI Assets for $10 Million Cash/Stock 2OTCBB-WNDM Announces LOI to Acquire VHGI Assets for $10 Million Cash/Stock 3SpineSmith Partners and GenOsteo Announce Collaborative Product Development Agreement 2(Date:11/7/2009)... 7 Patients reported C1-esterase i...apy in treating acute swelling attacks at any body...rder, according to data presented today at the 200...logy (ACAAI) Annual Meeting. The results come from...arallel with the ongoing, prospective, open label ...
(Date:11/6/2009)...RNewswire-FirstCall/ -- Oxygen Biotherapeutics, In... a previously approved reverse split of its common... Monday, Nov. 9, 2009 on a 1-for-15 split-adjusted...rade under the new symbol OXBT. The stock also wil...plit becomes effective. ,, "This reverse split ...
(Date:11/6/2009)... 6 DUSA Pharmaceuticals,...pany that is developing and marketing Levulan(...focused on patients with common skin conditions, a...tive Officer, will present a corporate overview at...Tuesday, November 10, 2009 at 10:00 a.m. ET at the...
Breaking Medicine Technology:Hereditary Angioedema Patients Report: C1-Esterase Inhibitor Concentrate Effective in Treating Acute Attacks, Helps Them Avoid Emergency Care 2Hereditary Angioedema Patients Report: C1-Esterase Inhibitor Concentrate Effective in Treating Acute Attacks, Helps Them Avoid Emergency Care 3Oxygen Biotherapeutics, Inc. Announces 1:15 Reverse Stock Split to Take Effect Nov. 9, 2009 2Oxygen Biotherapeutics, Inc. Announces 1:15 Reverse Stock Split to Take Effect Nov. 9, 2009 3Wolf reintroduction proposed in Scottish Highland test case 9286 1Wolf reintroduction proposed in Scottish Highland test case 9286 2Wolf reintroduction proposed in Scottish Highland test case 9286 3Sysmex America Debuts High end Sample Management System During AACC 52129 1Sysmex America Debuts High end Sample Management System During AACC 52129 2Sysmex America Debuts High end Sample Management System During AACC 52129 3Understanding Managed Markets 3A Effective Market Research Structures 26 Activities to Maximize Payer Access 26 Insights 13093 1Understanding Managed Markets 3A Effective Market Research Structures 26 Activities to Maximize Payer Access 26 Insights 13093 2